[CrossRef] [PubMed] [Google Scholar] LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial
doi: 10.1038/s41419-024-06435-w 51 DoLKLeeHMHaYSLeeCHKimJ
Atunci cnd vine vorba de pierderea n greutate , ar trebui s luai n considerare combinarea acesteia cu alte arztoare de grsimi, cum ar fi cofeina, sinefrina sau chiar extract de ceai verde cu coninut de EGCG
doi: 10.1152/ajprenal.00339.2006 224 WangMYuanQXieL
Pancreatic concerns All GLP-1 receptor agonists carry theoretical concerns about pancreatitis and pancreatic cancer risk
doi: 10.1038/nrendo.2013.255 3 ViganPParazziniFSomiglianaEVercelliniP